Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:23:39 EDT Sun 13 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CLDX - CELLDEX THERAPEUTICS INC - https://www.celldextherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CLDX - Q0.120.01·26.260.122.91+0.231.0808.318,1527,45822.64  23.55  22.49547.00  14.4017:23:32Jun 1415 min RT 2¢

Recent Trades - Last 10 of 7458
Time ETExPriceChangeVolume
17:23:32Q22.910.235,053
16:10:34Q22.910.2310,333
16:04:04Q22.910.231
16:04:00Q22.910.231
16:01:58Q22.910.23306
16:01:47Q22.910.231,260
16:01:46Q22.910.23293
16:01:23Q22.910.23170
16:01:06Q22.910.23382
16:01:03Q22.910.23550

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-14 10:48U:CLDXNews ReleaseCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
2025-06-12 18:01U:CLDXNews ReleaseCelldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
2025-06-10 16:01U:CLDXNews ReleaseCelldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
2025-06-06 08:01U:CLDXNews ReleaseCelldex Therapeutics Announces Election of Denice Torres to its Board of Directors
2025-05-08 16:01U:CLDXNews ReleaseCelldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-05 16:01U:CLDXNews ReleaseCelldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
2025-03-04 08:01U:CLDXNews ReleaseCelldex Therapeutics to Present at Upcoming Investor Conferences
2025-03-03 08:01U:CLDXNews ReleaseCelldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
2025-03-01 12:45U:CLDXNews ReleaseCelldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
2025-02-27 16:01U:CLDXNews ReleaseCelldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
2024-12-19 08:01U:CLDXNews ReleaseCelldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
2024-11-20 08:01U:CLDXNews ReleaseCelldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
2024-11-11 16:01U:CLDXNews ReleaseCelldex Therapeutics to Present at Upcoming Investor Conferences
2024-11-06 16:02U:CLDXNews ReleaseCelldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-10-26 17:43U:CLDXNews ReleaseCelldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
2024-10-25 08:01U:CLDXNews ReleaseCelldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
2024-09-25 10:45U:CLDXNews ReleaseCelldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
2024-09-16 08:01U:CLDXNews ReleaseCelldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
2024-09-12 16:01U:CLDXNews ReleaseCelldex Therapeutics to Present at Upcoming Investor Conferences
2024-08-08 16:01U:CLDXNews ReleaseCelldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update